Jellagen

Jellagen is pioneering a novel biomaterial platform using jellyfish-derived Collagen Type 0, offering a versatile, safe, and translatable alternative to traditional mammalian collagens. Its technology targets the high-growth regenerative medicine sector with applications in wound care, orthopedics, and cell culture. The company is building a strong scientific foundation through peer-reviewed publications and has announced strategic partnerships, positioning itself as an innovator in next-generation medical treatments. Jellagen operates as a private, likely pre-revenue entity, advancing its platform through research and development collaborations.

Proprietary platform for extracting and formulating 'Collagen Type 0,' a structurally intact, triple-helix collagen ethically sourced from jellyfish (Rhizostoma pulmo). It serves as a versatile, non-mammalian biomaterial for tissue engineering, regenerative medicine, and cell culture applications.

Jellagen competes with large manufacturers of bovine and porcine collagen (e.g., CollPlant, Integra LifeSciences) and other alternative collagen sources (e.g., fish, recombinant). Its differentiation lies in its unique source, which avoids mammalian disease and ethical concerns, and its strong foundational science. However, competitors have significant resources and established commercial footprints.